Literature DB >> 18951039

Antigens for cancer immunotherapy.

Michelle A Neller1, J Alejandro López, Christopher W Schmidt.   

Abstract

Progress in tumor immunology has not been translated to effective immunotherapies for cancer. Most of the current effort in basic and clinical research concentrates on generating effective immune responses against model or well characterized antigens, yet vaccines targeting defined antigens have been less clinically successful than those based on whole tumor cells or their extracts. This review considers characteristics of proteins that determine how effectively they might serve as targets of immune control, and how different sources of antigens have fared in clinical trials.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18951039     DOI： 10.1016/j.smim.2008.09.006

Source DB:  PubMed          Journal:  Semin Immunol        ISSN： 1044-5323            Impact factor:   11.130


  62 in total

1.  Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy.

Authors:  Yuhuan Li; Li-Xin Wang; Puiyi Pang; Zhihua Cui; Sandra Aung; Daniel Haley; Bernard A Fox; Walter J Urba; Hong-Ming Hu
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

Review 2.  Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.

Authors:  Michael Campoli; Robert Ferris; Soldano Ferrone; Xinhui Wang
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

3.  Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Authors:  An M T Van Nuffel; Daphné Benteyn; Sofie Wilgenhof; Lauranne Pierret; Jurgen Corthals; Carlo Heirman; Pierre van der Bruggen; Pierre G Coulie; Bart Neyns; Kris Thielemans; Aude Bonehill
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

Review 4.  Increasing the efficacy of tumor cell vaccines by enhancing cross priming.

Authors:  Brian M Andersen; John R Ohlfest
Journal:  Cancer Lett       Date:  2012-07-16       Impact factor: 8.679

Review 5.  Whole tumor antigen vaccines.

Authors:  Cheryl Lai-Lai Chiang; Fabian Benencia; George Coukos
Journal:  Semin Immunol       Date:  2010-03-30       Impact factor: 11.130

Review 6.  Antitumour dendritic cell vaccination in a priming and boosting approach.

Authors:  Alexandre Harari; Michele Graciotti; Michal Bassani-Sternberg; Lana E Kandalaft
Journal:  Nat Rev Drug Discov       Date:  2020-08-06       Impact factor: 84.694

Review 7.  Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.

Authors:  Michael R Olin; G Elizabeth Pluhar; Brian M Andersen; Rob Shaver; Nate N Waldron; Christopher L Moertel
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

Review 8.  Tumor lysate-loaded biodegradable microparticles as cancer vaccines.

Authors:  Vijaya B Joshi; Sean M Geary; Brett P Gross; Amaraporn Wongrakpanich; Lyse A Norian; Aliasger K Salem
Journal:  Expert Rev Vaccines       Date:  2014-01       Impact factor: 5.217

9.  Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity.

Authors:  Brian M Andersen; G Elizabeth Pluhar; Charles E Seiler; Michelle R Goulart; Karen S SantaCruz; Melissa M Schutten; Joyce P Meints; M Gerard O'Sullivan; R Timothy Bentley; Rebecca A Packer; Stephanie A Thomovsky; Annie V Chen; Dominik Faissler; Wei Chen; Matthew A Hunt; Michael R Olin; John R Ohlfest
Journal:  Cancer Res       Date:  2013-03-07       Impact factor: 12.701

Review 10.  Intracellular antigens as targets for antibody based immunotherapy of malignant diseases.

Authors:  Yangyang Wang; Xinhui Wang; Cristina R Ferrone; Joseph H Schwab; Soldano Ferrone
Journal:  Mol Oncol       Date:  2015-10-30       Impact factor: 6.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.